[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"obese-patients-with-bariatric-surgery\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:obese-patients-with-bariatric-surgery":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,51,77],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100622247","bariatric-surgery-and-gut-microbiota-changes-over-time-100622247",false,"NCT07381140","Bariatric Surgery and Gut Microbiota Changes Over Time","Longitudinal Evaluation of Gut Microbiota and Fecal Metabolome Following Roux-en-Y Gastric Bypass: Clinical Implications and Identification of Predictive Biomarkers","RYGB-MICROGUT","Inclusion Criteria (RYGB Group):\n\n* Age between 18 and 65 years.\n* Adults with a body mass index (BMI) ≥ 35 kg\u002Fm² with related comorbidities, or BMI ≥ 40 kg\u002Fm², who are candidates for Roux-en-Y gastric bypass (RYGB) surgery only.\n\nExclusion Criteria (RYGB Group):\n\n* Treatment with antibiotics within the last 3 weeks, or probiotics\u002Fprebiotics within the last 4-6 weeks, or systemic corticosteroids within the 8 weeks prior to baseline (T0).\n* Participation in dietary regimens or calorie restriction programs in the weeks prior to enrollment.\n* Chronic inflammatory bowel diseases (e.g., Crohn's disease, ulcerative colitis), ongoing enteric infections, or active neoplasms.\n* Previous organ transplant or ongoing systemic immunosuppressive therapy.\n* Pregnancy or breastfeeding.\n* Previous major gastrointestinal surgery.\n* Chronic alcohol consumption above moderate levels or substance use disorder.\n\nInclusion Criteria (Obese Control Group):\n\n* Age between 18 and 65 years.\n* Adults with BMI ≥ 30 kg\u002Fm² who are candidates for structured dietary treatment.\n\nInclusion Criteria (Healthy Control Group):\n\n* Age between 18 and 65 years.\n* Normal weight (BMI between 18.5 and 24.9 kg\u002Fm²).\n* Normal metabolic function: fasting glucose below threshold, normal ALT\u002FAST, no diagnosis of diabetes or metabolic syndrome.\n* No chronic gastrointestinal diseases or conditions that could alter the gut microbiota.\n\nExclusion Criteria (Obese Control and Healthy Control Group):\n\n* Use of antibiotics within the last 3 weeks or probiotics\u002Fprebiotics within the last 4-6 weeks.\n* Recent gastrointestinal surgery.\n* Pregnancy or breastfeeding.\n* Extreme diets or recent dietary changes.\n* Recent international travel that could have affected the gut microbiota.\n* Medications known to influence the gut microbiota (e.g., PPIs, metformin, steroids).\n* Active smoking or excessive alcohol consumption.\n* Significant gastrointestinal symptoms (chronic diarrhea or constipation).",true,"ALL","18 Years","65 Years",{"count":22,"type":23},100,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn how bariatric surgery affects gut bacteria and gut-related metabolic products over time in adults with obesity. The study includes adults aged 18 to 65 years who are undergoing Roux-en-Y gastric bypass (RYGB) surgery, as well as adults with obesity treated with diet alone and healthy normal-weight adults.\n\nThe main questions it aims to answer are:\n\nHow does bariatric surgery change the composition and diversity of gut bacteria over time? How are these changes related to weight loss and improvement of obesity-related health conditions?\n\nResearchers will compare people undergoing bariatric surgery with people with obesity treated with diet alone and with healthy normal-weight individuals to see if surgery leads to specific changes in gut bacteria and stool metabolites that are linked to better clinical outcomes.\n\nParticipants will:\n\nProvide stool samples at scheduled time points over 12 months Provide blood samples and undergo routine clinical assessments Take part in follow-up visits to monitor weight, metabolic health, and gastrointestinal symptoms",[27,28,29,30],"Obese Patients","Obese Patients With Bariatric Surgery","Gut Microbiota","Healthy Participants",[32,33,34,35,36,37],"gut microbiota","stool metabolome","obesity","bariatric surgery","Roux-en-Y gastric bypass","Long-read sequencing","NOT_YET_RECRUITING","2026-02-03",{"date":41,"type":42},"2026-02-05","ACTUAL",{"date":44,"type":23},"2026-04",{"date":46,"type":23},"2028-04",{"name":48,"class":49},"Azienda Ospedaliera Specializzata in Gastroenterologia Saverio de Bellis","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":50},"100607752","intravenous-tranexamic-acid-100607752","NCT07192640","Intravenous Tranexamic Acid","PERIOPERATIVE USE OF INTRAVENOUS TRANEXAMIC ACID FOR HIGH BMI PATIENTS GOING THROUGH BARIATRIC SURGERIES","TXA","Inclusion Criteria:\n\n* High-risk patients, with obesity, BMI more than 45,\n* Patients with Preexisting cardiovascular condition, Hypertension, diabetes, or coagulation disorders, thyroid dysfunction and pulmonary disorders.\n\nExclusion Criteria:\n\n* patients with active thromboembolic disorders.\n* Patients with preexisting renal dysfunction,","60 Years",{"count":61,"type":23},128,"INTERVENTIONAL",[64],"NA","Tranexamic acid is a promising option for minimizing blood loss in high-risk bariatric surgery patients, particularly in those with obesity, diabetes, and other comorbidities. When used appropriately, TXA can reduce the need for blood transfusions, maintain hemodynamic stability, and lower the incidence of complications related to blood loss.",[27,28,67],"Bleeding","2025-09-23",{"date":70,"type":42},"2025-09-25",{"date":72,"type":23},"2025-10-15",{"date":74,"type":23},"2026-03-30",{"name":76,"class":49},"Ain Shams University",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":59,"enrollmentInfo":84,"targetDuration":4,"studyType":62,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":50},"100589107","comparison-between-individualized-peep-ventilation-guided-by-driving-pressure-and-conventional-lung-protective-strategy-in-obese-patients-undergoing-laparoscopic-bariatric-surgery-100589107","NCT06950112","Comparison Between Individualized PEEP Ventilation Guided by Driving Pressure and Conventional Lung Protective Strategy in Obese Patients Undergoing Laparoscopic Bariatric Surgery","Comparison Between Individualized PEEP Ventilation Guided by Driving Pressure and Conventional Lung Protective Strategy in Obese Patients Undergoing Laparoscopic Bariatric Surgery: a Prospective Randomized Controlled Trial","Inclusion Criteria:\n\n1. patients who have a BMI 30-40 kg\u002Fm2\n2. American Society of Anesthesiologists (ASA) physical status II or III\n3. patients aged between 18 and 60 years,\n4. patients scheduled to undergo laparoscopic bariatric surgeries.\n\nExclusion Criteria:\n\n1. patients' refusal to participate in the study,\n2. previous history of thoracic surgery,\n3. Patients with a history of chest disease (COPD, emphysema, or pneumothorax),\n4. Patients with abnormal pre-operative chest radiographs, such as pneumonia and pleural effusion,\n5. Patients with right-side heart failure or impending failure,\n6. Patients with known hypovolemia, and Patients with increased intracranial pressure.",{"count":85,"type":23},60,[64],"this study to compare the ventilation in obese patients either using Driving pressure ventilation technique or conventional protective lung strategy all by using Lung ultrasound score",[28,89],"Lung Ultrasound Score","RECRUITING","2025-04-22",{"date":93,"type":42},"2025-04-29",{"date":95,"type":42},"2024-12-01",{"date":97,"type":23},"2026-11-01",{"name":99,"class":49},"Mahmoud Gamal Ahmed Arakeeb"]